Zai LabZLAB +0.76%64 Days Payable is 318.70 as of Mar. 2026, which is 44% below its 10-year median of 566.67. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.30 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 707 Biotechnology companies, Zai Lab ranks better than 65.35% on this metric.
Zai Lab's average Accounts Payable for the
three
months ended in Mar. 2026 was $133.9 Mil. Zai Lab's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $38.3 Mil.
Hence, Zai Lab's Days Payable for the
three
months ended in Mar. 2026 was 318.70.
The historical rank and industry rank for Zai Lab's Days Payable or its related term are showing as below:
ZLAB'
s Days Payable Range Over the Past 10 Years
Min: 221.12 Med: 566.67 Max: 196930.23
Current: 221.12
During the past 11 years, Zai Lab's highest Days Payable was 196930.23. The lowest was 221.12. And the median was 566.67.
ZLAB's Days Payable is ranked better than 65.35% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs ZLAB: 221.12
Zai Lab's Days Payable
increased
from Mar. 2025 (240.74) to Mar. 2026 (318.70).
It may suggest that Zai Labdelayed paying its suppliers.
Zai Lab Days Payable Related Terms
Zai Lab Days Payable Historical Data
* Premium members only.
The historical data trend for Zai Lab's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zai Lab's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's Days Payable distribution charts can be found below:
* The bar in red indicates where Zai Lab's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zai Lab's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (ZLAB) has a Days Payable of 318.70 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zai Lab and its competitors. This is 44% below median its historical median of 566.67. Over the past decade, Zai Lab's Days Payable has ranged from 221.12 to 196,930.23. According to the industry distribution chart, Zai Lab ranks #245 out of 707 companies in the Biotechnology industry, placing it in the top 34.7%.
Is Zai Lab's Days Payable too high?
Zai Lab's current Days Payable of 318.70 is 44% below median its 10-year median of 566.67. Over the past 10 years, this metric has ranged from a low of 221.12 to a high of 196,930.23. The Biotechnology industry median Days Payable is 113.76. Zai Lab's value of 318.70 is 180.2% above this industry median. Based on the distribution chart, Zai Lab ranks #245 out of 707 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Days Payable compare to TYRA and TRVI?
According to the Biotechnology industry distribution chart, Zai Lab ranks #245 out of 707 companies for Days Payable. This puts Zai Lab in the upper half of its industry. The industry median Days Payable is 113.76. Zai Lab's value of 318.70 is 180.2% above this benchmark. Historically, Zai Lab's own Days Payable has ranged from 221.12 to 196,930.23 over the past decade. While the company's 10-year median is 566.67 vs. the industry median of 113.76, Zai Lab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zai Lab's current Days Payable of 318.70 is 180.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zai Lab and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current Days Payable is 318.70, which is 44% below median its own 10-year median of 566.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.30, compared to a current price of $18.52 — trading 38.9% below its estimated fair value. The current Days Payable is 318.70, which is 44% below median its 10-year median of 566.67 and 180.2% above the Biotechnology industry median of 113.76. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zai Lab (ZLAB), the current Days Payable is 318.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $18.52 is trading 38.9% below its estimated GF Value™ of $30.30.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for ZLAB:
Days Payable: 318.70 (44% below median its 10-year median of 566.67)
GF Value™: $30.30 vs. price of $18.52 (38.9% below fair value)
Industry Position: 180.2% above the Biotechnology median (#245 of 707)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score
Get the complete analysis for ZLAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 
